Balancing protection versus immunopathology by RSV-specific memory CD8 T cells
Balancing protection versus immunopathology by RSV-specific memory CD8 T cells
批准号:
9977905
负责人:
Steven M Varga
金额:
$37.69万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2022-07-31
关键词:
AcuteAddressAnimal ModelAntibodiesAntibody titer measurementCD8-Positive T-LymphocytesCell physiologyCharacteristicsChildDataDevelopmentDiseaseElderlyEpitopesEquilibriumEthicsEvaluationFutureGoalsHumanImmunityImmunizationImmunocompromised HostIndividualKnowledgeLower Respiratory Tract InfectionLung diseasesMediatingMemoryMissionMorbidity - disease ratePathologyPopulationPropertyPublic HealthReagentRecombinantsResearchRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory syncytial virusSevere Acute Respiratory SyndromeStructure of parenchyma of lungT cell responseT memory cellT-LymphocyteTarget PopulationsTestingUnited StatesUnited States National Institutes of HealthVaccinatedVaccinationVaccine DesignViralViral Load resultVirusVirus DiseasesVirus Replicationbaseburden of illnesscostdesignhuman coronavirusimmunopathologyinfluenzavirusinsightmemory CD4 T lymphocytemortalitymouse modelnovel therapeutic interventionnovel vaccinesrespiratory virusvaccine candidatevirus infection mechanism
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease in children, the elderly and
immunocompromised individuals. There is currently no licensed RSV vaccine. High titers of RSV-specific
antibodies can provide protection against severe RSV-induced disease; however, even the highest antibody
titers fail to protect some individuals against RSV reinfection and disease. Thus, the correlates of protective
immunity against RSV remain unclear. Memory CD8 T cells can provide protective immunity against a wide
range of acute viral infections, including respiratory viruses such as influenza virus and the severe acute
respiratory syndrome (SARS) human coronavirus. In most virus infections, memory CD8 T cells mediate viral
clearance without causing substantial damage to the infected host. Because it is clear that antibodies alone
are not sufficient to provide complete protection against RSV infection, we hypothesized that induction of a
strong pre-existing RSV-specific memory CD8 T cell response in the absence of RSV-specific memory CD4 T
cells and antibodies would provide protective immunity against an RSV infection. In order to test our
hypothesis we modified an accelerated prime/boost approach to generate robust pre-existing memory CD8 T
cell populations specific to the immunodominant M282-90 epitope. Our preliminary data indicate that RSV-
specific memory CD8 T cells can significantly inhibit viral replication, but unexpectedly do so at the cost of
causing fatal immunopathology upon RSV challenge. Importantly, the immunopathology was not an inherent
property of the T cells, as RSV-specific memory CD8 T cells were capable of mediating protection without
immunopathology against a lethal challenge with a recombinant influenza virus expressing the RSV-derived
M282-90 epitope. Our data reveal that the design of a strictly T cell-based RSV vaccine could have severe
consequences. Thus, important knowledge gaps exist regarding how RSV-specific memory CD8 T cells
function to control RSV infection and the mechanisms that result in the development of immunopathology. The
goal of this proposal is to address these critical knowledge gaps and provide mechanistic insight into if memory
CD8 T cells can be manipulated to confer optimal protective immunity against RSV infection. We will achieve
these goals by pursuing the following three specific aims: Aim 1. Determine the mechanism of memory CD8 T
cell-mediated immunopathology following RSV infection. Aim 2. Investigate the characteristics of memory
CD8 T cells that enhance immunity and limit immunopathology after RSV challenge. Aim 3. Define the
optimal correlates of protection against RSV infection. The knowledge gained from these studies will provide
vital information regarding the correlates of protective immunity to RSV, information that will greatly impact the
design and evaluation of future RSV vaccine candidates.
!
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.4049/jimmunol.2000751
发表时间:
2022-02-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Hartwig SM, Miller AM, Varga SM]
通讯作者:
Varga SM
Deciphering the complexities of inflammasome activation following RSV infection
-
批准号:10655297
-
项目类别:
-
资助金额:$66.54万
-
财政年份:2022
-
负责人:Steven M Varga
-
依托单位:
Deciphering the complexities of inflammasome activation following RSV infection
-
批准号:10388682
-
项目类别:
-
资助金额:$23.39万
-
财政年份:2022
-
负责人:Steven M Varga
-
依托单位:
Deciphering the complexities of inflammasome activation following RSV infection
-
批准号:10807884
-
项目类别:
-
资助金额:$38.99万
-
财政年份:2022
-
负责人:Steven M Varga
-
依托单位:
RSV-induced inflammation in the brain
-
批准号:10252048
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2020
-
负责人:Steven M Varga
-
依托单位:
Role of TLR4 in Coronavirus Infection
-
批准号:7860303
-
项目类别:
-
资助金额:$18.66万
-
财政年份:2009
-
负责人:Steven M Varga
-
依托单位:
Immunopathology mediated by RSV-specific CD4 T cells
-
批准号:7895292
-
项目类别:
-
资助金额:$3.9万
-
财政年份:2009
-
负责人:Steven M Varga
-
依托单位:
Role of TLR4 in Coronavirus Infection
-
批准号:7701085
-
项目类别:
-
资助金额:$22.41万
-
财政年份:2009
-
负责人:Steven M Varga
-
依托单位:
Immunopathology mediated by RSV-specific CD4 T cells
-
批准号:7568970
-
项目类别:
-
资助金额:$35.65万
-
财政年份:2007
-
负责人:Steven M Varga
-
依托单位:
Immunopathology mediated by RSV-specific CD4 T cells
-
批准号:8013503
-
项目类别:
-
资助金额:$34.94万
-
财政年份:2007
-
负责人:Steven M Varga
-
依托单位:
Immunopathology mediated by RSV-specific CD4 T cells
-
批准号:7758806
-
项目类别:
-
资助金额:$35.29万
-
财政年份:2007
-
负责人:Steven M Varga
-
依托单位:
Immunopathology mediated by RSV-specific CD4 T cells
-
批准号:7356021
-
项目类别:
-
资助金额:$35.65万
-
财政年份:2007
-
负责人:Steven M Varga
-
依托单位:
Immunopathology mediated by RSV-specific CD4 T cells
-
批准号:7209559
-
项目类别:
-
资助金额:$36.34万
-
财政年份:2007
-
负责人:Steven M Varga
-
依托单位:
GENETIC DETERMINANTS MEDIATING VIRUS INDUCED LUNG INJURY
-
批准号:6208861
-
项目类别:
-
资助金额:$3.24万
-
财政年份:2000
-
负责人:Steven M Varga
-
依托单位:
GENETIC DETERMINANTS MEDIATING VIRUS INDUCED LUNG INJURY
-
批准号:6388787
-
项目类别:
-
资助金额:$4.02万
-
财政年份:2000
-
负责人:Steven M Varga
-
依托单位:
海外基金